Purpose-built for biotech-fintech operational depth
Every layer of this stack was specified for biotech-specific workflows and settlement velocity. No horizontal platform re-skinned for life sciences — architecture native to the problem.
Four layers. One coherent system.
Data ingestion — lab instruments, EHR feeds, regulatory filings normalized at source.
Collateral engine — healthcare data assets priced, versioned, and audit-logged against settlement requirements.
Settlement rails — transaction finality matched to biotech capital cycles, not generic T+2 equity timelines.
Compliance membrane — Hong Kong regulatory controls embedded at the transport layer, not bolted on post-build.
API-first. No rip-and-replace.
REST and event-stream APIs surface against existing lab LIMS, ERP, and trading infrastructure. Existing systems stay in place; the adapter layer absorbs the translation work.
Data sovereignty controls are specified at schema level. Audit trails meet HKMA and SFC reporting requirements by architectural default — not by post-deployment configuration.
Evaluate the architecture before the sales call.
The full architecture overview document covers data flow, API surface, compliance controls, and integration prerequisites. Request it directly.